Health Care·Pharmaceuticals·$4.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.14 | N/A | +0.00% |
management commentary, guidance changes, and full analysis available with Pro.
| +0.00% |
Tone: Neutral
Management maintained a neutral tone during the call, emphasizing ongoing strategic efforts. They did not provide any forward guidance.
Management did not provide specific guidance for the upcoming quarters.
The company remains focused on its strategic initiatives.
Ligand Pharmaceuticals reported an EPS of $0.14, which was in line with expectations, though no revenue figures were disclosed. The stock reacted positively, rising by 1.02%. The lack of guidance may leave investors uncertain about future performance, but the steady EPS suggests stability in the company's current operations.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AMERICAN FINL GROUP
Feb 11, 2013